Found pairs obesity-medicine clinicians with one-to-one behaviour coaching and 503A compounding, with compounded tirzepatide at $359 a month month-to-month, billed every 28 days, and as little as $239 a month if twelve months are paid up front. Check which plan a number belongs to before comparing it.
Obesity medicine also brings a habit that matters here: it looks past the scale to the metabolic picture underneath. That earns Found partial marks on being believed and on honest metabolic framing, which is more than most weight-focused providers manage.
Here is how Found reads against each promise of the Whole-Woman Charter. Each promise is marked none, partial or strong; price is shown but is never part of the rating. GLP-1 medications are not a treatment for endometriosis.
What Found’s published price covers, taken from its own pages and checked October 2026. “Not listed on their site” means we could not find it published.
The plan bundles clinician oversight, 503A titration and structured coaching. For a condition you live with rather than resolve, having a named person who checks in is worth more than it usually gets credit for. Dose fit scores strong; lasting care and cost both sit at partial, reflecting a service that publishes its structure but prices it differently across plan lengths.
The coaching frame is behaviour — eating, movement, routine. It is not built to account for a condition where fatigue and pain are unpredictable and where a plan that assumes a steady week may simply not survive a bad one. Care here is not organised around hormonal or gynecologic history, so how well the coaching adapts depends on the individual coach rather than on the model. Worth establishing early.
Put these to Found in writing, and keep the reply.
Found's coaching is its real strength. It rates mid-Charter because the whole apparatus is built around weight and behaviour rather than around a person managing a chronic condition. For many readers that will still be the right trade, provided the plan length behind the price suits them.
What is above comes from what this provider chooses to publish, and providers revise their terms without saying so — treat it as a starting point and check it yourself. Havelle is editorial, not clinical: none of this is medical advice, and GLP-1 medications are not a treatment for endometriosis.